Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy

Wednesday, May 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of a study on pevifoscorvir sodium monotherapy for chronic hepatitis B infection. Participants showed a sustained reduction in HBV antigen levels after 96 weeks of treatment. This suggests that the drug may be an effective option for HBeAg-positive patients. Further research may be needed to confirm these findings.
Price reaction · baseline $5.74 (2026-05-26 close) · hit pre-market · 7 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sustained reduction of HBV antigen levels observed.
  • Monotherapy shows potential for chronic hepatitis B treatment.
  • 96 weeks of treatment indicates long-term efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is the main finding of the study?

The study found a sustained reduction in HBV antigen levels after 96 weeks of treatment.

What type of patients were involved in the study?

The study involved HBeAg-positive participants with chronic hepatitis B infection.

What treatment was tested in the study?

The study tested 300 mg of pevifoscorvir sodium monotherapy.

How long was the treatment duration?

The treatment duration was 96 weeks.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare pevifoscorvir sodium chronic hepatitis B HBV treatment HBeAg-positive
Last updated: May 27, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →